Masahiro Kagabu1, Tadahiro Shoji2, Kazuyuki Murakami2, Hideo Omi2, Tatsuya Honda2, Fumiharu Miura2, Yoshihito Yokoyama3, Hideki Tokunaga4, Tadao Takano4, Tsuyoshi Ohta5, Dai Shimizu6, Naoki Sato6, Shu Soeda7, Takafumi Watanabe7, Hidekazu Yamada8, Hideki Mizunuma3, Nobuo Yaegashi4, Satoru Nagase5, Toru Tase8, Toru Sugiyama2. 1. Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Iwate, 020-0065, Japan. mkagabu@iwate-med.ac.jp. 2. Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Iwate, 020-0065, Japan. 3. Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan. 4. Department of Obstetrics and Gynecology, Tohoku University School of Medicine, 1-1 Seiryo-cho, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. 5. Department of Obstetrics and Gynecology, Yamagata University School of Medicine, 2-2-2 Iidanishi, Yamagata, 990-9585, Japan. 6. Department of Obstetrics and Gynecology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan. 7. Department of Obstetrics and Gynecology, School of Medicine Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan. 8. Department of Gynecology, Miyagi Cancer Center, 47-1 Aishima, Natori, Miyagi, 981-1293, Japan.
Abstract
OBJECTIVE: The aim of this study was to compare the efficacy of nedaplatin-based concurrent chemoradiotherapy (CCRT) with that of cisplatin-based CCRT in patients with cervical cancer. METHODS: The medical records of patients with cervical cancer who had undergone CCRT between 2003 and 2007 were retrospectively reviewed. Of these, 129 patients were treated postoperatively with CCRT (n = 52) or primary CCRT (n = 77). A total of 29 patients were treated with nedaplatin-based postoperative CCRT and 23 patients were treated with cisplatin-based postoperative CCRT. A total of 28 patients were treated with nedaplatin-based postoperative CCRT, and 49 patients were treated with cisplatin-based postoperative CCRT. Progression-free survival (PFS) and overall survival (OS) were compared between the treatment groups. RESULTS: With postoperative CCRT, there were no significant differences in recurrence rate (P = 1.0000), PFS (log-rank: P = 0.8503), and OS (log-rank: P = 0.8926) between the two treatment groups. With primary CCRT, there were no significant differences in PFS (log-rank: P = 0.7845) and OS (log-rank: P = 0.3659). The frequency of acute toxicity was not significantly different between the cisplatin-based postoperative CCRT group and the nedaplatin-based postoperative CCRT group. CONCLUSIONS: Nedaplatin-based postoperative CCRT is an effective and well-tolerated regimen for both early-stage and advanced-stage cervical cancer patients.
OBJECTIVE: The aim of this study was to compare the efficacy of nedaplatin-based concurrent chemoradiotherapy (CCRT) with that of cisplatin-based CCRT in patients with cervical cancer. METHODS: The medical records of patients with cervical cancer who had undergone CCRT between 2003 and 2007 were retrospectively reviewed. Of these, 129 patients were treated postoperatively with CCRT (n = 52) or primary CCRT (n = 77). A total of 29 patients were treated with nedaplatin-based postoperative CCRT and 23 patients were treated with cisplatin-based postoperative CCRT. A total of 28 patients were treated with nedaplatin-based postoperative CCRT, and 49 patients were treated with cisplatin-based postoperative CCRT. Progression-free survival (PFS) and overall survival (OS) were compared between the treatment groups. RESULTS: With postoperative CCRT, there were no significant differences in recurrence rate (P = 1.0000), PFS (log-rank: P = 0.8503), and OS (log-rank: P = 0.8926) between the two treatment groups. With primary CCRT, there were no significant differences in PFS (log-rank: P = 0.7845) and OS (log-rank: P = 0.3659). The frequency of acute toxicity was not significantly different between the cisplatin-based postoperative CCRT group and the nedaplatin-based postoperative CCRT group. CONCLUSIONS:Nedaplatin-based postoperative CCRT is an effective and well-tolerated regimen for both early-stage and advanced-stage cervical cancerpatients.
Entities:
Keywords:
Concurrent chemoradiotherapy; Nedaplatin; Radical hysterectomy; Uterine cervical cancer
Authors: C W Whitney; W Sause; B N Bundy; J H Malfetano; E V Hannigan; W C Fowler; D L Clarke-Pearson; S Y Liao Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544
Authors: W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: H M Keys; B N Bundy; F B Stehman; L I Muderspach; W E Chafe; C L Suggs; J L Walker; D Gersell Journal: N Engl J Med Date: 1999-04-15 Impact factor: 91.245